OmniAb, Inc. (OABI)

NASDAQ: OABI · IEX Real-Time Price · USD
5.39
+0.20 (3.85%)
At close: Mar 27, 2024, 4:00 PM
5.47
+0.08 (1.48%)
After-hours: Mar 27, 2024, 7:55 PM EDT
3.85%
Market Cap 605.54M
Revenue (ttm) 34.16M
Net Income (ttm) -50.62M
Shares Out 116.86M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 704,280
Open 5.24
Previous Close 5.19
Day's Range 5.16 - 5.39
52-Week Range 3.14 - 6.72
Beta n/a
Analysts Strong Buy
Price Target 9.20 (+70.69%)
Earnings Date Mar 20, 2024

About OABI

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic cand... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 95
Stock Exchange NASDAQ
Ticker Symbol OABI
Full Company Profile

Financial Performance

In 2023, OmniAb's revenue was $34.16 million, a decrease of -42.17% compared to the previous year's $59.08 million. Losses were -$50.62 million, 126.6% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price forecast is $9.2, which is an increase of 70.69% from the latest price.

Price Target
$9.2
(70.69% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program update...

7 days ago - Business Wire

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wedn...

4 weeks ago - Business Wire

OmniAb to Participate in Two Investor Conferences in March

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March. TD Cowen 44th Annual Healthcare Co...

5 weeks ago - Business Wire

OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry's first and only transgenic chicken host syste...

3 months ago - Business Wire

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) held its first Research & Technology virtual event earlier today, during which members of the management team reviewed ...

4 months ago - Business Wire

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and...

4 months ago - Business Wire

OmniAb to Participate in Two Investor Conferences in November

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in November. Stifel 2023 Hea...

5 months ago - Business Wire

OmniAb Appoints Steve Love to its Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial e...

5 months ago - Business Wire

OmniAb Announces Agenda for its Research & Technology Virtual Event

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:0...

5 months ago - Business Wire

OmniAb to Hold Research & Technology Virtual Event on November 9

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. ...

5 months ago - Business Wire

OmniAb to Participate in Two Investor Conferences in September

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in September. H.C. Wainwright 25th Annual Gl...

7 months ago - Business Wire

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner p...

8 months ago - Business Wire

OmniAb Announces the Passing of Director Sunil Patel

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #OABI--OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week. The Board of Directors and leadership of OmniAb extend thei...

8 months ago - Business Wire

OmniAb to Report Second Quarter 2023 Financial Results on August 10

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial ma...

8 months ago - Business Wire

OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) announced the launch of OmniDeep™ at the 19th Annual PEGS Boston Conference and Expo: The Essential Protein Engineering & Cell Therapy ...

11 months ago - Business Wire

OmniAb Reports First Quarter 2023 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates. “Our fi...

11 months ago - Business Wire

OmniAb to Report First Quarter 2023 Financial Results on May 11

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May ...

11 months ago - Business Wire

OmniAb to Participate in Upcoming Investor Conferences in May

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May. H.C. Wainwright BioConnect Investor...

1 year ago - Business Wire

OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program update...

1 year ago - Business Wire

OmniAb to Report Fourth Quarter 2022 Financial Results on March 30

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thur...

1 year ago - Business Wire

OmniAb to Participate in Three Upcoming Investor Conferences

OmniAb to Participate in Three Upcoming Investor Conferences

1 year ago - Business Wire

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb ...

Other symbols: LGND
1 year ago - Business Wire

OmniAb to Participate in Two Upcoming Investor Conferences

EMERYVILLE, Calif.

1 year ago - Business Wire

OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell

EMERYVILLE, Calif.

1 year ago - Business Wire

OmniAb Announces Completion of Spin-Off and Business Combination

EMERYVILLE, Calif.

Other symbols: LGND
1 year ago - Business Wire